Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luconatuzumab plus anlotinib in HR+/HER2- breast cancer with brain metastases
ChiCTR2500110614Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan and anlotinib in hormone receptor-positive/HER2-negative breast cancer and brain metastases, sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective response rate of central nervous system (CNS-ORR). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
sacituzumab govitecananlotinib
03
Conditions
hormone receptor-positive/HER2-negative breast cancerbrain metastases
Beyond the preview
Go deeper on ChiCTR2500110614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110614.